MedPath

Efficacy of thrice-weekly long-acting insulin degludec provided by nurses in handicapped patients with type 2 diabetes on maintenace hemodialysis teratment

Phase 4
Recruiting
Conditions
type2 diabetes on hemodialysis treatment
Registration Number
JPRN-UMIN000038149
Lead Sponsor
Organization for Kidney and Metabolic Disease Ttreatment
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

1. type 1 diabetes 2. self-injection is impossible

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
control of blood glucose status at 3 months after fixting insulin dosage
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath